Olaparib approved in the EU as monotherapy for treatment of adults with BRCA1/2-mutated metastatic castration-resistant prostate cancer

It has been approved for use in those who have progressed following a prior therapy that included a new hormonal agent. Approval was based on a subgroup analysis of the Phase III PROfound trial, in which it was associated with improved PFS and OS vs enzalutamide or abiraterone.

Biospace Inc.